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Objective To evaluate long-term outcomes of laronidase enzyme replacement therapy in patients with attenu-
ated mucopolysaccharidosis type I.
Study design Retrospective analyses of case notes, laboratory results, and data from clinical trials were used
to evaluate urinary glycosaminoglycans, forced vital capacity (FVC), 6-minute walk test (6MWT), height-for-age Z
score, cardiac valve function, corneal clouding, and visual acuity in 35 patients with attenuated mucopolysaccharidosis
type I (Hurler-Scheie and Scheie syndromes) for up to 10 years following the initiation of laronidase therapy.
Results Statistically significant (P < .001) reductions in mean urinary glycosaminoglycan levels relative to baseline
were observed 6 months after treatment initiation and were sustained throughout follow-up. Disease remained stable
after treatment initiation with no statistically significant changes in mean FVC, 6MWT, or height-for-age Z score. At
last assessments, mitral and aortic valve function remained stable in 65% (22/34) of patients; corneal clouding
remained stable in 78% (18/23); visual acuity remained stable in 33% (8/24) and improved in 42% (10/24) of pa-
tients. Younger patients (<10 years at treatment initiation) maintained disease measures closer to norms for age
for FVC, 6MWT, and height and showed fewer deteriorations in mitral and aortic valve disease and corneal cloud-
ing compared with patients aged ≥10 years at treatment initiation.
Conclusion Laronidase treatment resulted in disease stabilization in the majority of patients with a mean follow-
up of 6.1 years. Data suggest that early treatment may result in better outcomes. (J Pediatr 2016;178:219-26).
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder affecting approximately1:100 000 live births.1 MPS I is characterized by deficiency of the lysosomal enzyme alpha-L-iduronidase. Thisdeficiency causes accumulation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate in cells through-
out the body, resulting in the characteristic, multisystem phenotype typified by short stature, abnormal facies, hepatomegaly,
cognitive impairment, joint contractures, skeletal abnormalities, cardiac disease, respiratory disorders, corneal clouding, visual
impairment, and cervical myelopathy.2 Disease severity and rate of progression are variable. At its most severe, MPS I (Hurler
syndrome) presents in infancy with death within 10 years as a result of cardiorespiratory failure and neurologic disease.1,2
Patients with attenuated MPS I (Hurler-Scheie and Scheie syndromes) may survive into adulthood, generally without cogni-
tive impairment but with significant morbidity.3
Treatment options for MPS I include enzyme replacement therapy (ERT) with laronidase (Aldurazyme; Sanofi Genzyme,
Boston, Massachusetts, and BioMarin Pharmaceutical, Novato, California), he-
matopoietic stem cell transplantation (considered most beneficial for patients with
Hurler syndrome younger than 2 years of age with developmental quotients of
>70), and symptom-based and palliative care.2
Interpretation of outcome reports for laronidase is complicated by disease
rarity, clinical heterogeneity, and a paucity of long-term outcome studies. We
add to the collective experience of laronidase treatment in MPS I by reporting
clinical outcomes across several disease manifestations for 35 patients with
attenuated MPS I (Hurler-Scheie and Scheie syndromes) treated for up to
10 years.
6MWT 6-minute walk test
ERT Enzyme replacement therapy
FVC Forced vital capacity
GAG Glycosaminoglycan
MPS I Mucopolysaccharidosis type I
uGAG Urinary glycosaminoglycan
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Methods
Clinical data were reviewed retrospectively for living and de-
ceased patients with a diagnosis of MPS I classified clinically
(Table I; available atwww.jpeds.com)and/orbymolecular analy-
sis as having attenuated disease, who started laronidase treat-
ment between 2000 and 2009 at the Department of Genetic
Medicine, St Mary’s Hospital, Manchester, UK, and who
did not undergo hematopoietic stem cell transplantation.One
patient was excluded because clinical notes were not available
for review.
The study involved anonymous data collected from case
notes; ethics committee approval was not required. Good Clini-
cal Practice standards were adhered to throughout.
For each patient, the last data collected before ERT initia-
tion were used as the baseline for clinical outcomesmeasured.
ERT was initiated within 6 months of baseline measurement
of clinical measures in 89% of cases. In the majority of these,
the ERTwas started within 1month of baselinemeasurement.
Patients were prescribed weekly infusions of laronidase at the
approved dose (100 U/kg). Follow-up included data collected
within 6 months of baseline and annual clinical outcome
measures.
Outcome measures included urinary glycosaminoglycan
(uGAG) excretion, 6-minute walk test (6MWT), forced vital
capacity (FVC), height-for-age Z score, cardiac status (mea-
sured by left ventricular function and aortic and mitral valve
function), corneal clouding, and visual acuity. Duration of
follow-up varied for each outcome. Not all patients provided
data at every assessment because of a lack of cooperation, learn-
ing difficulties, or inability to complete some outcome mea-
sures adequately (such as 6MWT, FVC in young children).
uGAGs were measured as described previously4 and re-
ported as mean percentages of baseline values. Respiratory
function was measured by spirometry and reported as FVC
in liters as a percentage of the predicted volume for height.
The 6MWT was conducted by physiotherapists as described
previously4 and reported as meters walked in 6 minutes. Pa-
tients’ height-for-age Z scores via the use of World Health
Organization standards4 were recorded up to the age of
21 years (for older patients, the sex-specific reference for
19 years of age was used).
Cardiac status was assessed with echocardiography and
included mitral and aortic valve function (regurgitation or
stenosis) recorded subjectively as none/mild/moderate/
severe according to the cardiologist’s report; valve thickening
alone was not recorded.
Corneal clouding was recorded subjectively as none/mild/
moderate/severe by the treating physician or ophthalmolo-
gist.Visual acuity was documented and converted to ameasure
of vision loss according to the The International Classification
of Diseases, Ninth Revision codes (best corrected if available;
best uncorrected if no corrected measurement was available).
For aortic valve,mitral valve, corneal clouding, and visual acuity,
changes in categories (normal, mild, or moderate involve-
ment) were noted at follow-up time points relative to baseline.
Antibody levels to laronidase were measured in all pa-
tients by Sanofi Genzyme as described previously,4 either as
part of the laronidase phase 3 clinical trial, or as standard
pharmacovigilance analysis. In 1 patient with high antibody
titers (patient #17, see the section “Additional Investiga-
tions”), inhibition of cellular uptake of enzyme was tested at
St Mary’s hospital via methods described by Saif et al.5
Statistical Analyses
For uGAG, height-for-age Z scores, % predicated FVC, and
6MWT endpoints, a repeated measures mixed model was
applied. The covariates included age group (3 categories: ≤4,
5-9, and ≥10 years at treatment initiation), sex, ethnicity, du-
ration on therapy, and a duration on therapy × age group in-
teraction effect, with a patient-level random slope and intercept
effect. Baseline value also was included as a covariate for the
height-for-age Z scores, % predicted FVC, and 6MWT end-
points. Linear slope estimates from mixed models are from
baseline through patients’ follow-up. The repeated measures
mixed model analysis was based on observed data; missing data
were not imputed. Figure 1 presents the mean values by age
group for each year on ERT (±SE) via the use of observed cases.
Outcomes were considered statistically significant if the
P value was ≤ .05. Aortic valve, mitral valve, corneal cloud-
ing, and visual acuity shift analyses for age categories present
the patient’s change in score from baseline using last obser-
vation carried forwardmethodology (using the last postbaseline
value). For each endpoint, the shift analysis classifies a pa-
tient’s last postbaseline value as having worsened relative to
baseline (deteriorated), remained the same as baseline (stable),
or improved relative to baseline (improved). These results are
presented overall and stratified by baseline age.
Results
Thirty-five patients with attenuated MPS I were prescribed
laronidase throughout the study. One discontinued ERT
after 1 year because the patient declined weekly intravenous
infusions and clinic attendance. Three patients died during
follow-up. Patient characteristics are shown in Table I.
Urinary GAGs
Baseline uGAG data were available for 91% (32/35) of pa-
tients. Mean uGAG levels decreased by more than 50% from
baseline within 6 months of laronidase therapy regardless of
age at initiation. Reductions remained between 50% and 90%
of baseline values throughout follow-up (Figure 1, A). Per-
centage reduction from baseline was statistically significant
(P < .001) at all time points (6-months to 7 years). On the basis
of the repeated measures mixed model analysis, female pa-
tients had, on average, 9.2% less reduction in uGAG levels over
time than male patients (P = .01).
Height-for-Age Z Score
Baseline height-for-age Z scores were available for 89% (31/
35) of patients. At baseline, the mean height-for-age Z score
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of children <10 years of age was closer to the expected norm
than for patients aged ≥10 years at the start of ERT (mean of
−1.60 and −3.50, respectively; P ≤ .05). Patients ≤4 years of age
at baseline had height-for-age Z scores closer to the normal
range throughout follow-up (P < .001) than patients ≥10 years
of age at baseline (Figure 1, B); however, within an age cohort,
the changes in height-for-age Z score up to 7 years follow-up
were not statistically significant (slope for patients ≥10 years
at baseline: −0.13 [SEM 0.36]; 5-9 years: −0.05 [SEM 0.56]; ≤4
years: −0.02 [SEM 0.42]). Height-for-age Z score deterio-
rated after 7 years of therapy in one patient (see the section
“Additional Investigations”). Patients of Asian descent (all
Pakistani) had lower height-for-age Z scores over time com-
pared with patients of European origin (P < .001).
Respiratory Function
Baseline spirometry data, available for 66% (23/35) of pa-
tients, showed a mean of 51% of predicted FVC for height
(Figure 1, C). Nine of 12 missing patients at baseline were <5
years of age; spirometry tests were not performed for these pa-
tients.No statistically significant difference in change in%pre-
dicted FVC was found compared with baseline for any of the
3 age groups. Outcomes indicated largely stable disease with a
change in% predicted FVC for children ≤4 years: +4.83 (SEM:
3.4); children 5-9 years: +4.44 (SEM 4.4); patients ≥10 years:
+0.23 (SEM2.06).On the basis of the repeatedmeasuresmixed
model analysis, female patients had, on average, % predicted
FVC scores 8.8 points greater over time compared with male
patients (P = .03).Patients of Asianorigin had lower%predicted
FVC compared with patients of European origin (P < .001).
Six-Minute Walk Test (6MWT)
Baseline data were available for 63% (22/35) of patients. There
was no statistically significant change in the 6MWT from base-
line (change in 6MWT slope for children ≤4 years: +31.48
[SEM: 29.9]; 5-9 years: +26.47 [SEM: 34.3]; and patients ≥10
Figure 1. Mean values by age group for each year on ERT. A, Percentage change in uGAGs (mean ± SEM). Data represent
mean percent change in uGAG compared with baseline uGAG. B, Height-for-age Z score (mean ± SEM). For patients up to 21
years of age, height-for-age Z scores are reported via World Health Organization standards; for older patients, the sex-specific
reference for 19 years of age was used. C, Percent predicted FVC (mean ± SEM). Data represent FVC in liters as a percent-
age of the predicted volume for height. D, 6MWT (mean ± SEM). Data shown are meters walked in 6 minutes.
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years: +15.45 [SEM: 17.84]; Figure 1, D). After 6 years, mean
values deteriorated because of a decline in 1 patient (see the
section “Additional Investigations”).
Cardiac Assessments
At baseline, 14% (5/35) of patients had normal mitral valve
function; 77% (27/35) had mild stenosis/regurgitation, and
9% (3/35) had moderate stenosis/regurgitation. Of the 34
patientswith follow-updata (to 10 years),65%(22/34) remained
stable with respect to baseline at their last assessment, 32%
(11/34) deteriorated, and 3% (1/34) improved (Table II and
Figure 2, A). Seventy-two percent (8/11) of deteriorations
occurred in patients with mild valve involvement at baseline
(5 developed moderate and 3 developed severely impaired
function); 18% (2/11) occurred in patients with moderate
involvement at baseline (1 developed severe disease and 1 re-
quired surgery), and 1 patient with normal function at base-
line developedmild mitral valve stenosis/regurgitation. Fewer
children aged <10 years experienced deterioration compared
with patients aged ≥10 years at treatment initiation (14% vs
45% at last assessment; Table II).
At baseline, 66% (23/35) of patients had normal aortic valve
function; 26% (9/35) had mild and 9% (3/35) had moderate
stenosis/regurgitation. Of the 34 patients for whom follow-
up data (to 10 years) were available, 65% (22/34) remained
stable with respect to baseline at their last assessment, 29%
deteriorated (10/34), and 6% (2/34) improved (Table II and
Figure 2, B). Ninety percent (9/10) of deteriorations oc-
curred in patients with normal valve function at baseline
(6 developed mild and 3 developed moderate stenosis/
regurgitation); 1 patient with mild aortic valve involvement
at baseline developed severe stenosis/regurgitation. Fewer chil-
dren aged <10 years at treatment initiation deteriorated com-
pared with patients aged ≥10 years (14% vs 40%; Table II).
Corneal Clouding
Baseline assessment of corneal clouding was available for
77% of patients (27/35); all had evidence of corneal
clouding—67% (18/27) with mild and 15% (4/27) with mod-
erate clouding; 11% of patients (3/27) had severe clouding, 2
of whom underwent penetrating keratoplasty during the study.
The grafts were clear at last review. Two patients had grafts at
Table II. Shift data for mitral and aortic valves, corneal
clouding, and visual acuity at patients’ last assess-
ments (1-10 years) overall, and according to patient age
at treatment initiation
Clinical
measures
Baseline age,
y (n)
At last follow-up (1-10 y)
Deteriorated Stable Improved
Mitral valve Overall 11/34 (32%) 22/34 (65%) 1/34 (3%)
≤4 (9) 2/9 (22%) 7/9 (78%) 0
5-9 (5) 0 5/5 (100%) 0
Total <10 (14) 2/14 (14%) 12/14 (86%) 0
≥10 (20) 9/20 (45%) 10/20 (50%) 1/20 (5%)
Aortic valve Overall 10/34 (29%) 22/34 (65%) 2/34 (6%)
≤4 (9) 2/9 (22%) 7/9 (78%) 0
5-9 (5) 0 4/5 (80%) 1/5 (20%)
Total <10 (14) 2/14 (14%) 11/14 (79%) 1/14 (7%)
≥10 (20) 8/20 (40%) 11/20 (55%) 1/20 (5%)
Corneal
clouding
Overall 4/23 (17%) 18/23 (78%) 1/23 (4%)
≤4 (8) 1/8 (13%) 6/8 (75%) 1/8 (13%)
5-9 (3) 0 3/3 (100%) 0
Total <10 (11) 1/11 (9%) 9/11 (82%) 1/11 (9%)
≥10 (12) 3/12 (25%) 9/12 (75%) 0
Visual acuity Overall 6/24 (25%) 8/24 (33%) 10/24 (42%)
≤4 (7) 4/7 (57%) 0 3/7 (43%)
5-9 (3) 0 2/3 (67%) 1/3 (33%)
Total <10 (10) 4/10 (40%) 2/10 (20%) 4/10 (40%)
≥10 (14) 2/14 (14%) 6/14 (43%) 6/14 (43%)
Figure 2. Change in A, mitral valve and B, aortic valve involvement over time in patients treated with laronidase. The data
show the number of patients who deteriorated, remained stable, or improved at their last assessment compared with baseline
in terms of mitral or aortic valve stenosis and regurgitation.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 178
222 Laraway et al
baseline; 1 had severe, persistent graft clouding and the
other had a clear graft which remained clear during 4 years
of follow-up. Twenty-three of 34 patients had follow-up
data up to 8 years (Table II and Figure 3, A); 78% (18/23)
remained stable, 17% (4/23) deteriorated (2 patients pro-
gressed from moderate to severe visual loss, and 2 from severe
to profound), and 4% (1/23) had improved from baseline to
last assessment. Of children aged <10 years at treatment ini-
tiation, 9% deteriorated compared with 25% of patients aged
≥10 years (Table II).
Visual Acuity
Data were available for 74% (26/35) of patients at baseline; 35%
(9/26) had normal vision, 42% (11/26) had mildly impaired
vision, 4% (1/26) had moderate vision loss, 15% (4/26) had
severe vision loss, and 4% (1/26) had profound vision loss.
Twenty-four patients had follow-up data up to 8 years: 33%
(8/24) remained stable; 25% (6/24) deteriorated with respect
to baseline (5 patients developed mild vision loss and one pa-
tient’s visual acuity deteriorated from severe to profound); and
42% (10/24) of patients improved (Table II and Figure 3, B).
A greater percentage of children aged <10 years at baseline de-
teriorated compared with patients aged ≥10 years at baseline
(40% versus 14%; Table II).
Additional Investigations
During follow-up, 74% (25/34 of patients tested) were found
to have antibodies to laronidase. Of the 25 patients with an-
tibodies, titers decreased with time in 44% (11/25) with 16%
(4/25) testing negative for antilaronidase antibodies at their
last assessment. Titers increased in 8% (2/25) of patients. In
1 patient aged ≤4 years at baseline (#17), antibodies to
laronidase inhibited cellular uptake of enzyme (by more than
80%), which may explain this patient’s apparent reduced re-
sponsiveness to ERT (Figure 4; available at www.jpeds.com).
Discussion
Laronidase is a disease-modifying treatment for patients with
attenuated MPS I. Long-term outcome studies published to
date include only 8 patients followed for 6 years or more.6-8
With two-thirds of patients in this study receiving treatment
for 6-10 years, we provide further insights into long-term
outcome, which may help guide patients’ and physicians’ ex-
pectations. Because this was a retrospective study, complete
patient data were not available at all time points. The amount
of missing data varied depending on the endpoint and patient,
with the cardiac status endpoints missing the least amount (18%
on average) and visual acuity assessments missing the most
(51% on average).
This study demonstrated a biochemical reduction and sub-
sequent stabilization, but not normalization, of mean uGAGs.
Clinically, there was significant stabilization of mean values for
FVC, 6MWT, and height-for-age Z score. Cardiac valve status
and corneal clouding stabilized in the majority of patients up
to 10 years’ follow-up. Disease stabilization without major de-
terioration over a number of years can be considered a clini-
cally important treatment outcome, given the progressive nature
of this disease, which ultimately leads to significant morbid-
ity, disability, and premature death in patients with Hurler-
Scheie phenotypes and morbidity in patients with Scheie
phenotypes.1,2,9 In the absence of treatment, data from the phase
3 clinical trial of laronidase have shown that patients with MPS
I experience a decline in pulmonary function and 6MWT
scores, as well as an increase in their GAG values.4
Results of this study suggest better outcomes for height, %
predicted FVC, and 6MWT in patients who started treatment
at earlier ages. Children <10 years of age at baseline main-
tained measures closer to age-related norms compared with
patients≥10 years at baseline.Without treatment, deterioration
would be expected on the basis of differences in baseline values
Figure 3. Change in A, corneal clouding and B, visual acuity over time in patients treated with laronidase. The data show the
number of patients who deteriorated, remained stable, or improved at their last assessment compared with baseline.
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for children,≤ 4 years, 5-9 years, and ≥10 years (Figure 1, B-D).
Disease stabilization in children <10 years of age at baseline is
particularly salient because children diagnosed at an early age
are likely to have earlier onset, more severe, and more rapidly
progressive disease.10 In our cohort, all 21 patients in the ≥10
age group at baseline had presenting symptoms prior to age
10 (average 3.9 years, range prenatal-9 years).
As mentioned previously, the baseline data for this patient
group show a greater disease burden in the absence of treat-
ment comparedwith the younger age groups.Although disease
is stabilized in most patients, those diagnosed at a young age
whodid not initiate treatment untilmuch latermaintain greater
disease burden throughout. Maintaining clinical status closer
to age-expected norms may have profound implications for
psychosocial development11 and for reducing the limitations
that MPS I may incur on daily life.12 Three of the 35 patients
in the study died during the review period; 2 of cardiac com-
plications (1 following surgery for mitral valve replacement)
and 1 of sudden death (which may also be related to cardiac
involvement). All 3 were older than 10 years of age at the start
of ERT, had well-established disease at the time of ERT, and
received treatment for 3-6 years. These outcomesmay support
early initiation of treatment.
Better outcomes in children treated before 10 years of age
were also suggested by shift analyses formitral valve, aortic valve,
and corneal clouding (Table II). For visual acuity, more de-
teriorations were observed in children <10 years compared with
children >10 years at treatment initiation, although improve-
ments occurred at similar rates for both age groups. Loss of
visual acuity in MPS I is thought to be related to dermatan
sulfate deposition in the cornea13; however, vision also may be
affected by other ocular manifestations of MPS I, such as swell-
ing of the optic nerve, optic atrophy, glaucoma, and retinal
pigment epithelium degeneration,14 for which the effects of ERT
may differ and are not well understood. Improvement in visual
acuity without improvement in corneal clouding has been re-
ported previously.15 Vision loss is a significant complication
of MPS I, which may negatively impact independent living and
quality of life. Although outcomes of this study are encour-
aging, difficulties in measurement (small patient numbers, the
subjective nature of corneal clouding assessment, test-to-test
variability, difficulties of assessing young children, and deter-
mining whether changes are within the normal or mild loss
of vision range) make results difficult to interpret.
It is notable that aortic andmitral valve stenosis/regurgitation
remained stable in the majority of patients. Cardiac involve-
ment is a frequent finding in patients with attenuated MPS I3,16
and a major cause of morbidity and mortality.17 Given that
follow-up was prolonged, impaired function may have been
expected to occur more widely. In patients with cardiac valve
involvement at baseline (88% or 30/34 for mitral and 35% or
12/34 for aortic valve involvement), stability was seen in the
majority of patients (67% or 20/30 and 8/12 for both mitral
and aortic valve involvement). Deterioration was seen more
commonly in patients who were older at the time of treat-
ment initiation. Importantly, the vast majority of patients
younger than 10 years of age at start of ERT had only mild
cardiac disease at baseline.We do note that the clinical course
of cardiac disease was highly variable, with no clear reason for
why some patients progress and others stabilize. Although age
and the extent of involvement at start of ERT may be influ-
encing factors, as discussed previously, there are likely other
complex individual factors at play. Moreover, cardiac assess-
ment as recorded for the purposes of this study has limitations
including difficulties in accurately assessing function via
echocardiography (especially in patients whose cooperationmay
be limited), and only subjective and nonstandardized assess-
ment of stenosis/regurgitation was reported. As such, the
grading system used here may make interpretation of small
changes in disease severity difficult to interpret.
Further limitations in interpretation of results include the
heterogeneity of the patient population, which may have in-
fluencedmean outcomes. Patients of Asian origin in this cohort,
for example, were affected more severely in terms of height and
pulmonary function compared with patients of European
origin, a factor that may relate to differing genetic profiles (all
patients of Asian origin were Pakistani and homozygous for
the L490P mutation; there were no patients of European origin
who were homozygous for this mutation).3 Other outcome
measures also may be affected by patient demographics. GAG
excretion is known to be affected by age18 and in this study was
shown to be affected by sex. FVC may be influenced by age,
sex (as shown in this study), as well as ethnicity.19 Age also may
be a factor in the 6MWT, because performance may depend
on attention span and the ability to comply with instruc-
tions. The 6MWT also may be affected by cardiorespiratory
function, joint pain, flexibility, and stature, all of which may
be variably affected by ERT. Mean outcomes for 6MWT,
height-for-age Z score, FVC, and GAGs were also negatively
influenced by outcomes in 1 patient in this study, who devel-
oped antibody-induced cellular uptake inhibition of enzyme.
Many patients, especially those with low endogenous enzyme
levels, develop antibodies to laronidase but total antibody titers
are not predictive of compromised treatment and, often,
patients do not suffer clinical effects.4 Inhibition of catalytic
activity by itself may not be functionally significant but inhi-
bition of cellular uptakemay compromise treatment response.5,20
Immune system responses to exogenous enzyme should, there-
fore, be assessed and taken into consideration when evaluat-
ing treatment outcomes. We do appreciate that long-term
outcomes with treatment would be best addressed in a well-
controlled prospective study; however, such studies are diffi-
cult to perform in the rare disease space, and it may be that
even longer-term results over a number of centers are re-
quired to achieve a significant conclusion.
Results of this study are similar to previously reported short-
term outcomes and demonstrate that laronidase reduces GAG
storage4,6,8,12,15,21-26 and may stabilize or improve respiratory
function,4,6,12,15,24,26 growth,6,15,21,24 mobility,4,12,15,22,24 some cardiac
manifestations,6,12,15,24,25 corneal clouding,6,12 and visual
acuity.6,12,14,15 This study suggests that treatment effectiveness
persisted for up to 10 years; however, as shown in previous
studies, treatment may not prevent deterioration in all
patients.6,7,12,27 Although GAG clearance may be a biomarker
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of treatment response, irreversible damage secondary to GAG-
induced inflammatory responses may occur. Early treat-
ment, before irreversible change takes place, is likely the most
important factor in influencing outcomes,24,25,28,29 although
this view is not supported universally.27 Other factors may
include differences in disease severity and progression and
affected systems, immune responses (discussed previously),
and tissue-specific factors that affect response, including
biodistribution of protein, burden of storage, residual enzyme
activity, and irreversibility of disease due to downstream
cascades. Delays in diagnosis continue despite treatment
availability10 and highlight the need for greater awareness
among pediatricians of common MPS I presenting symp-
toms, which can be nonspecific for attenuated disease (Table I).9
Previous studies have shown that the optimal time for initia-
tion of therapy is before the onset of symptoms,24,25,30 al-
though unless diagnosed due to a family history (26% of
patients in this study presented because of family history), very
few children initiate ERT this early. Newborn screening may
provide a means of ensuring that children with MPS I are
treated early enough to prevent disease manifestations.25 ■
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Figure 4. Impact of outcomes in patient #17 (who exhibited antibody-induced cellular uptake inhibition of enzyme) on mean
treatment outcomes for A, uGAG loss (mean ± SEM); B, height-for-age Z score (mean ± SEM); C, FVC ratio (mean ± SEM);
and D, 6MWT (mean ± SEM).
Table I. Patient characteristics
Ethnicity European origin: 22
Asian origin 12: (all Pakistani)
Uncertain: 1
Sex 13 male; 22 female
Age at presentation 26% (9/35 patients) presented because of family history (affected siblings/family members). Of the remaining 26
patients, the mean age of presentation was 3.85 years; median 4 y; range 0.25-9 y
Symptoms at presentation (some patients
had multiple reasons/symptoms)
Hepatosplenomegaly (n = 8); umbilical hernia (n = 5); joint stiffness (n = 7); ENT and/or respiratory problems (n = 6);
dysmorphism including short stature, skeletal dysplasia, “trigger” fingers, scoliosis, enlarged head (n = 15);
developmental delay (n = 3); abnormal gait (n = 1); corneal clouding (n = 2); poor appetite (n = 1)
Age at baseline Mean 11.5 y; median 11.3 y; range 0.5 - 23.1 y
≤4 y: n = 9
5-9 y: n = 5
≥10 y: n = 21
ERT dose Laronidase i.v. infusions at 100 U/kg body weight weekly
Years of follow-up Mean 6.1 y; median 6 y; range 1-10 y
(1 y: n = 1; 2 y: n = 2; 3 y: n = 1; 4 y: n = 7; 5 y: n = 1; 6 y: n = 7; 7 y: n = 7; 8 y: n = 2; 9 y: n = 3; 10 y: n = 4)
ENT, ear, nose, and throat; i.v., intravenous.
November 2016 ORIGINAL ARTICLES
226.e1Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I
